Caroline deRichemond, CRNP, CLS, FNLA
Clinical Lipid Specialist, Fellow of the National Lipid Association, Geisinger Cardiology
Actions
Caroline deRichemond, CRNP, CLS, FNLA, recognized for her knowledge of lipid disorders, is a Certified Lipid Specialist (CLS) and is a Fellow of the National Lipid Association (FNLA) associated with Geisinger Health in Pennsylvania. She has more than 25 years of experience in adult health, cardiovascular prevention and lipidology. She has clinic at multiple Geisinger Health System sites, including Wilkes Barre, Scranton, Danville, Lewistown, and State College.
Her academic roles include Instructor of Lipidology, Assistant Professor at Geisinger Commonwealth School of Medicine. Caroline is frequently invited to present at professional conferences focused on lipidology and reducing cardiovascular risk, such as the American Association of Nurse Practitioners national meeting, Pennsylvania Coalition of Nurse Practitioners clinical conference, National Lipid Association, and the American Society for Preventative Cardiology.
She holds the position of Board Officer for the Northeast Lipid Association, and was also appointed as Co-Chair for TEACH-ASCVD, a national lipid trial led by the National Lipid Association. Caroline is a Mentor for the Lipid Scholars program of the National Lipid Association. She has twice received the National Lipid Association President’s Service Award in 2023 and 2024 for her leadership.
Currently, she participates in four lipid trials at Geisinger, has been published on Familial Hypercholesterolemia, and the transition from pediatric to adult lipid care. Caroline's contributions span clinical practice, education, and advocacy, earning her respect as a leader in inherited Lipid disorder management and cardiovascular risk reduction.
Area of Expertise
Lipids 2025: Improving Cardiovascular Health
This session is to provide an update of Lipid management for use in clinical practice. This will include an overview of the current recommendations for screening Lipids across the life span, lifestyle modification, and Lipid therapy for primary and secondary cardiovascular prevention.
Discussion of the current Lipid guidelines including: 2018 Multi-societal. 2022 United States Preventative Taskforce , 2022 therapies, American College of Cardiology Non-Statin therapies, 2023 National Lipid Association and American Society of Preventative Cardiology LDL-C.
Common Lipid disorders, secondary causes of dyslipidemia, and when to refer to the Lipid Clinic for advanced therapies and testing will be reviewed.
Ladies and Lipids: Assessing Cardiometabolic Risk
This session will focus on primary prevention of Atherosclerotic Cardiovascular Disease (ASCVD) by examining female sex-specific cardiovascular risk factors at each stage of life. Lipids are impacted during normal hormonal changes throughout a woman's life cycle- during adolescence, pre-pregnancy, pregnancy, pre- and perimenopause, menopause, and at older ages. ASCVD remains to be the number one cause of women’s death in the United States. Missed or delayed diagnosis, and undertreatment contributes to ASCVD such as elevated Lipoprotein (a) and Familial Hypercholesterolemia. Women’s cardiovascular rates are increasing among younger women <55 years as well as an increase suboptimal cardiovascular health during pregnancy. There is an increase in metabolic syndrome leading to prevalence of dyslipidemias. Younger women are less likely to be treated less and to achieving therapeutic targets. Previous guidelines acknowledge sex-specific risk enhancing factors for lipid management in women for Cardiovascular prevention. There is a continued need for sex-specific guidelines for evaluation and management of lipids. Future research should focus on increasing enrollment of women in lipid trials. This session is to enhance clinical practice in the management of cardiovascular/cardiometabolic health of women across the lifespan.
2023 Lipid Management for Clinical Practice
This session is to provide an update of Lipid management for use in clinical practice. This will include an overview of the current recommendations for screening across the lifespan, lifestyle modification, and Lipid therapy for primary and secondary cardiovascular prevention.
Discussion of the current Lipid guidelines including; Multi- Societal 2018, USPSTF 2022, ACC Non statin therapies 2022, NLA and ASPC LDL-C measurement and control as performance measures 2023 and applying into clinical practice.
Common Lipid disorders, secondary causes of dyslipidemia, and when to refer to the Lipid Clinic for advanced therapies and testing will be reviewed.
Caroline deRichemond, CRNP, CLS, FNLA
Clinical Lipid Specialist, Fellow of the National Lipid Association, Geisinger Cardiology
Actions
Please note that Sessionize is not responsible for the accuracy or validity of the data provided by speakers. If you suspect this profile to be fake or spam, please let us know.
Jump to top